Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (GB:0HF9)
LSE:0HF9
Holding GB:0HF9?
Track your performance easily
See the Price Targets and Ratings of:
0HF9 Analyst Ratings
Strong Buy
8 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0HF9 Stock 12 Month Forecast
Average Price Target
$17.33
▲(76.21% Upside)
| Highest Price Target$21.00 | Average Price Target$17.33 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Jefferies
Assigned
12/17/24
Morgan Stanley
Downgraded
12/12/24
J.P. Morgan
Reiterated
11/12/24
TD Cowen
Assigned
11/07/24
Guggenheim
Reiterated
11/07/24
Cantor Fitzgerald
Reiterated
11/06/24
Leerink Partners
Reiterated
11/06/24
Bank of America Securities
Reiterated
11/06/24
Needham
Reiterated
11/06/24
Wells Fargo
$18
Buy
83.02%
Upside
Reiterated
08/08/24
Amicus's PomOp Outperforms with Strong Sales and Market Share Growth, Securing a Buy Rating
Stifel Nicolaus
$20
Buy
103.36%
Upside
Reiterated
07/08/24
Amicus (FOLD) Gets a Buy from Stifel Nicolaus
Goldman Sachs
$16→$14
Hold
42.35%
Upside
Reiterated
05/10/24
Amicus Therapeutics (FOLD) PT Lowered to $14 at Goldman SachsGoldman Sachs analyst Salveen Richter lowered the price target on Amicus Therapeutics (NASDAQ: FOLD) to $14.00 (from $16.00) while maintaining a Neutral rating.
Best Analysts Covering Amicus
Which Analyst Should I Follow If I Want to Buy GB:0HF9 and Sell After:
1 Month
xxx
Success Rate
11/17 ratings generated profit
Average Return
+9.41%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +9.41% per trade.
3 Months
xxx
Success Rate
9/13 ratings generated profit
Average Return
+11.18%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +11.18% per trade.
1 Year
Success Rate
8/13 ratings generated profit
Average Return
+26.73%
reiterated a buy rating 2 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +26.73% per trade.
2 Years
xxx
Success Rate
7/17 ratings generated profit
Average Return
+3.16%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 41.18% of your transactions generating a profit, with an average return of +3.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0HF9 Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
11
7
7
9
9
Buy
3
1
3
5
5
Hold
3
1
1
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
9
11
15
16
Each month's total comprises the sum of three months' worth of ratings.
0HF9 Financial Forecast
0HF9 Stock Forecast FAQ
What is GB:0HF9’s average 12-month price target, according to analysts?
Based on analyst ratings, Amicus Therapeutics’s 12-month average price target is $17.33.
What is GB:0HF9’s upside potential, based on the analysts’ average price target?
Amicus Therapeutics has 76.21% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Amicus Therapeutics a Buy, Sell or Hold?
Amicus Therapeutics has a consensus rating of Strong Buy, which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.
What is Amicus Therapeutics’s share price target?
The average share price target for Amicus Therapeutics is $17.33. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $21.00 ,and the lowest forecast is $12.00. The average share price target represents 76.21% Increase from the current price of $9.835.
The highest analyst share price target is $21.00 ,and the lowest forecast is $12.00. The average share price target represents 76.21% Increase from the current price of $9.835.
What do analysts say about Amicus Therapeutics?
Amicus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of Amicus Therapeutics?
To buy shares of GB:0HF9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.